A Tumor-Organoid-Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer,Advanced Therapeutics

当前位置： X-MOL 学术 › Adv. Therap. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Tumor-Organoid-Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer
Advanced Therapeutics ( IF 3.7 ) Pub Date : 2022-08-17 , DOI: 10.1002/adtp.202200093
Xingyue Wang _{1,

2} , Xiaohuan Lu _{2,

3} , Bo Cai ₂ , Xiaoqiong Li _{2,

3} , Danyi Zou _{1,

2} , Shijun Lei _{1,

2} , Luming Xu _{1,

2} , Guobin Wang ₃ , Lin Wang _{1,

2} , Zheng Wang _{2,

3}

Affiliation

Investigation of clinical actionable targets is crucial for the individual treatment of patients with advanced colorectal cancer (CRC). A complete platform integrating the molecular profiling and prediction of drug reactivity is currently scarce. An integrated precision medicine approach which combines high-throughput sequencing platform with microfluidic organoid drug testing system is established. Capture sequencing identifies 6 drug targetable genes and 13 candidate drugs for a stage III colorectal cancer patient. The drug sensitivity is confirmed by using patient-derived organoids (PDOs) model and microfluidic drug testing system. With this integrated precision medicine approach, the optimal drugs including Afatinib, Dacomitinib, and Osimertinib are successfully identified. The platform provides a practical method to guide the clinical therapies for colorectal cancer patients.

中文翻译：

用于预测结直肠癌药物敏感性的基于肿瘤类器官的精准医学平台

临床可操作靶点的研究对于晚期结直肠癌 (CRC) 患者的个体化治疗至关重要。目前还缺乏一个整合药物反应性分子谱分析和预测的完整平台。建立了将高通量测序平台与微流控类器官药物检测系统相结合的一体化精准医疗方法。捕获测序为一名 III 期结直肠癌患者确定了 6 个药物靶向基因和 13 个候选药物。通过使用患者来源的类器官 (PDO) 模型和微流体药物测试系统来确认药物敏感性。通过这种综合精准医学方法，成功鉴定了阿法替尼、达克替尼和奥希替尼等最佳药物。

更新日期：2022-08-17

点击分享查看原文

点击收藏

阅读更多本刊最新论文